EGFR and breast cancer: In addition, siramesine, a lysosomotropic agent, and lapatinib, a potent double tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor, ErbB-1) and ErbB-2 [114], can co-operatively induce ferroptosis-mediated cell death in BC cells [149,150].